Dicerna Pharmaceuticals
Delivering RNAi-based breakthrough therapies to improve lives.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $3.3b Valuation: $3.3b 17.1x EV/Revenue -23.2x EV/EBITDA | Acquisition | |
| Total Funding | 000k | ||
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 500 % | 283 % | 613 % | 18 % | (1 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (5000 %) | (1000 %) | (552 %) | (68 %) | (74 %) | (112 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (6000 %) | (1467 %) | (522 %) | (69 %) | (66 %) | (78 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 2860 % | 587 % | 340 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Dicerna Pharmaceuticals, now a wholly owned subsidiary of Novo Nordisk, operates at the forefront of ribonucleic acid interference (RNAi) therapeutic development. The company was founded in 2006 by Douglas Fambrough, John "J.J." Bujalski, and Nobel laureate Phillip Sharp, leveraging their collective expertise to pioneer new treatments. A significant milestone in the company's journey was its acquisition by Novo Nordisk in a transaction valued at approximately $3.3 billion, which was completed in December 2021. This acquisition integrated Dicerna's specialized RNAi capabilities, particularly its proprietary GalXC™ and GalXC-Plus™ technology platforms, into Novo Nordisk's broader research and development strategy. Before the acquisition, Dicerna was a publicly traded entity on the Nasdaq exchange under the ticker symbol DRNA.
The core of Dicerna's business is the discovery and development of therapies that use RNAi to silence genes responsible for causing or contributing to a range of diseases. The company's GalXC™ technology platform is engineered to create stable, potent, and highly targeted RNAi therapies. This platform has been instrumental in building a pipeline of drug candidates. Initially, the focus was on liver-targeted treatments for rare conditions, cardiometabolic diseases, viral infections, and chronic liver ailments. Building on this foundation, the GalXC-Plus™ platform extends the application of RNAi to tissues beyond the liver, opening up potential treatments for neurodegenerative diseases and pain. The company's business model involves both advancing its internal pipeline of drug candidates and forming strategic collaborations with major pharmaceutical companies. These partnerships provide non-dilutive funding through upfront payments, milestone achievements, and potential future royalties, while also expanding the reach and application of its RNAi technology. Dicerna's primary clients are these large pharmaceutical partners and, ultimately, patients with serious unmet medical needs across various therapeutic areas.
Keywords: RNAi therapeutics, gene silencing, GalXC platform, Novo Nordisk subsidiary, drug development, rare diseases, cardiometabolic, biopharmaceutical, strategic partnerships, clinical trials